![](https://investorshub.advfn.com/uicon/427786.png?cb=1468618745)
Sunday, May 16, 2021 12:39:11 PM
(PDF) Peripherally Administered Nanoparticles Target ...
www.researchgate.net › publication › 236461466
Apr 23, 2013 · Toon Stegmann is employed by Mymetics BV. ... using a phosphatidylinositol 3-kinase inhibitor of macropinocytosis ... taken up by bone marrow cells as a function of the PI3K inhibitor (Ly294002 ...
https://www.researchgate.net/publication/236461466_Peripherally_Administered_Nanoparticles_Target_Monocytic_Myeloid_Cells_Secondary_Lymphoid_Organs_and_Tumors_in_Mice
(PDF) Fusion of human neutrophil phagosomes with lysosomes in ...
www.researchgate.net › publication › 11878031_Fusion
selective tyrosine kinase inhibitors (33) suggest the involvement. of tyrosine phosphorylation in intact human neutrophils. In ad- ... Pascale Peyron, Isabelle Maridonneau-Parini and Toon Stegmann.
https://www.researchgate.net/publication/11878031_Fusion_of_human_neutrophil_phagosomes_with_lysosomes_in_vitro_Involvement_of_tyrosine_kinases_of_the_Src_family_and_inhibition_by_mycobacteria
(PDF) Metabolic fate of plasma membrane diacylglycerols in ...
www.researchgate.net › publication › 21520255
Toon Stegmann. Mymetics SA; ... kinase inhibitor . R . 59022 . and the lipase inhibitor . RG . 80267 . on the metabolism . of ["CJDOG . Radioactivity recovered in different cellular lipids from ..
Metabolic Fate of Plasma Membrane Diacylglycerols in NIH 3T3 Fibroblasts*
https://www.researchgate.net/publication/21520255_Metabolic_fate_of_plasma_membrane_diacylglycerols_in_NIH_3T3_fibroblasts
Fibroblast Growth Factor basic Protein, Human recombinant - Merck
www.merckmillipore.com › INTL › en
Fibroblast Growth Factor basic Protein, Human recombinant The Fibroblast Growth Factor-basic (FGF-b) is a heparin binding growth factor which stimulates the proliferation of a wide variety of cells including mesenchymal, neuroectodermal & endothelial cells.
Recent MYMX News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 01/02/2024 06:16:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 01:00:38 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/13/2023 05:15:20 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 01:53:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2023 08:42:46 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 10/17/2023 07:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 01:00:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/18/2023 10:02:57 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2023 09:01:04 PM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM